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Additional Outcomes and Subgroup Analyses of NXY-059
for Acute Ischemic Stroke in the SAINT I Trial
Kennedy R. Lees, MD, FRCP; Antonio Davalos, MD; Stephen M. Davis, MD, FRACP;
Hans-Christoph Diener, MD; James Grotta, MD; Patrick Lyden, MD; Ashfaq Shuaib, MD;
Tim Ashwood, PhD; Hans-Goran Hardemark; Warren Wasiewski, MD; Ugochi Emeribe, PhD;
Justin A. Zivin; for the SAINT I Investigators
Background and Purpose—NXY-059 is a free radical-trapping neuroprotectant demonstrated to reduce disability from
ischemic stroke. We conducted analyses on additional end points and sensitivity analyses to confirm our findings.
Methods—We randomized 1722 patients with acute ischemic stroke to a 72-hour infusion of placebo or intravenous
NXY-059 within 6 hours of stroke onset. The primary outcome was disability at 90 days, as measured by the modified
Rankin Scale (mRS), a 6-point scale ranging from 0 (no residual symptoms) to 5 (bed-bound, requiring constant care).
Additional and exploratory analyses included mRS at 7 and 30 days; subgroup interactions with final mRS; assessments
of activities of daily living by Barthel index; and National Institutes of Health Stroke Scale (NIHSS) neurological scores
at 7 and 90 days.
Results—NXY-059 significantly improved the distribution of the mRS disability score compared with placebo at 7, 30, and
90 days (Cochran-Mantel-Haenszel test P0.002, 0.004, 0.038, respectively; 90-day common odds ratio 1.20; 95% CI,
1.01 to 1.42). The benefit was not attributable to any specific baseline characteristic, stratification variable or subgroup
interaction. Neurological scores were improved at 7 days (odds ratio [OR], 1.46; 95% CI, 1.13, 1.89; P0.003) and the
Barthel index was improved at 7 and 30 days (OR, 1.55; 95% CI, 1.22, 1.98; P0.0001; OR, 1.27; 95% CI, 1.01, 1.59;
P0.02).
Conclusions—NXY-059 within 6 hours of acute ischemic stroke significantly reduced disability. Benefit on neurological
scores and activities of daily living was detectable early but not significant at 90 days; however, our trial was
underpowered to measure effects on the neurological examination. The benefit on disability is not confounded by
interactions and is supported by other outcome measures. (Stroke. 2006;37:2970-2978.)
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Treatment for acute ischemic stroke improves outcome.Specialist stroke unit care reduces mortality and disabil-
ity and is generally applicable. Aspirin is also generally
applicable and offers a small benefit. Reperfusion strategies
such as administration of alteplase (recombinant tissue plas-
minogen activator [rt-PA]) can offer substantial benefit to
improve neurological function and reduce disability but are at
present delivered to only a small proportion of stroke patients,
and their use is associated with practical difficulties and a
modest risk of hemorrhage.1 We need a treatment that can
protect brain tissue from ischemic damage until spontaneous
or therapeutic reperfusion occurs, and that can be adminis-
tered safely and easily.2 It should be suitable for use in a wide
range of patients, because even modest benefits that can be
delivered to a majority of patients will have greater public
health impact than substantial benefit derived by a few. The
search for such a neuroprotectant has been arduous and so far
no therapy has been generally approved.
We have recently reported reduction in disability associated
with use of the free radical-trapping neuroprotectant, NXY-059,
in acute ischemic stroke: the Stroke-Acute Ischemic NXY
Treatment (SAINT I) trial.3 NXY-059 is a well-tolerated agent
that is believed to act through interruption of the ischemic
cascade at the level of free radical induced injury.4–6 This is a
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late stage in the process of both permanent and transient
ischemia that occurs in brain and vascular endothelium cells.
The SAINT I trial demonstrated that NXY-059 treatment
was associated with a significant reduction in global disabil-
ity, achieved without affecting mortality or causing obvious
safety problems.3 Disability was first in a prespecified hier-
archy of end points; the trial was not statistically significant
on the end points lower in the hierarchy. A closer examina-
tion is justified of the effects on disability and neurological
status, and on possible sources of interaction or confounding
influence. Here we report detailed results of exploratory
analyses of the trial because these demonstrate that the
secondary outcome measures (scores of neurological function
and activities of daily living) were strongly positive when
measured within weeks of study treatment, that they are
supportive of the disability findings, and that the disability
findings themselves show consistency across a range of
subgroups.
Methods
The study design and patient population have been described else-
where.3 Briefly, this was a double-blind, randomized, and placebo-
controlled trial that assessed the effect of a 72-hour infusion of
NXY-059 on disability and neurological outcomes in patients treated
within 6 hours of an acute ischemic stroke. Patients otherwise
received standard care for acute stroke. We stratified randomization
for country, National Institutes of Health Stroke Scale7 (NIHSS)
score at baseline, side of cerebral infarct (ie, left or right hemi-
sphere), and intention to cotreat with alteplase using a dynamic
algorithm to maintain balance of prognostic factors between treat-
ment groups.8 The randomization scheme also forced allocation of
patients so that the average time to treatment at each center was not
4 hours at any time during enrolment. The trial had appropriate
regulatory and ethical committee approval in all countries and
patients or their representatives gave informed consent to participa-
tion. The steering committee developed the trial protocol, approved
the statistical plan, had full access to the data, wrote the manuscript,
and was responsible for decisions regarding publication. The aca-
demic authors vouch for the veracity and completeness of the data
and data analyses.
Outcome Measures
We assessed patients at enrolment and recorded outcomes after 7, 30,
and 90 days, taking the last rating for our primary outcome, which
was based on the modified Rankin Scale (mRS).9 The mRS is a
disability scale that awards scores in 6 categories ranging from 0 (no
residual symptoms) through 5 (bed-bound, requiring constant nurs-
ing care). Investigators were trained, tested, and certified in use of
mRS, using a DVD method developed specifically in preparation for
this trial. Assessments of stroke severity at baseline, 7 days, and 90
days were based on a neurological rating scale, the NIHSS, which
quantifies the neurological examination, and were conducted by
observers trained and certified in its use.7 NIHSS scores range from
0 (normal) to 42 (most severe). A hierarchy of additional outcome
measures was prespecified after the mRS,3 starting with the NIHSS
and then Barthel index (BI).10 The BI is an activities of daily living
scale that awards scores in increments of 5 ranging from 0 (totally
dependent) through 100 (no help required for activities of daily
living).
Statistical Analysis
The analyses were prespecified and followed the intention-to-treat
principle: all patients are included within this analysis who were
randomized, received any study infusion, and had any follow-up
assessment performed. Our primary end point was mRS at 90 days or
last rating, analyzed across the whole distribution of scores by the
Cochran-Mantel-Haenszel test (CMH), adjusted for stratification
variables (NIHSS, side of infarct and alteplase use), and using
modified ridit scores, ie, midrank/(number of observations1), to
account for ordered categories.11 A significant benefit on this end
point was considered sufficient for us to declare a positive trial.3,12
Odds ratios were calculated by proportional odds logistic regression,
which assumes a common odds ratio across all cut-points of the
mRS, but were used only as an estimate of treatment effect. The odds
ratios were adjusted in the same way as for the primary end point.
Whereas the odds ratio gives an estimate of treatment effect, the
CMH test gives a more accurate probability value. For all analyses,
deaths were included within the worst outcome category (mRS, 5;
NIHSS, 42; BI, 0) and last available rating was used to replace any
missing values in survivors. Patients who had recurrent stroke during
follow-up were included in our analysis, even though disability from
the index stroke will thus have been overestimated. The sample size
was chosen to have 90% power to detect a common odds ratio of 1.3.
The change from baseline in the NIHSS score at 90 days (“change
score”) was second in our hierarchy of tests and termed coprimary in
the study protocol; joint testing with mRS was not proposed.3 It was
analyzed using analysis of covariance adjusted for baseline variables
of NIHSS, side of infarct and use of alteplase; in calculating the
change from baseline, deaths were awarded the worst score, 42.
Because the NIHSS analysis by ANCOVA was compromised
through failure to meet statistical assumptions over distributions of
changes in score (essentially, the distribution was not Gaussian,
being both skewed and bimodal; Figure 1), we have here used
exploratory analyses of final NIHSS score using the approach
prespecified for our primary end point and the same method of
interpretation as reported in other recent acute stroke trials.13,14 For
overall assessment of effect on NIHSS, we have used the CMH test,
adjusted in the same way as for mRS; for estimation of odds ratios,
we divided the final NIHSS scores into 2 groups: one with scores of
0 to 1, representing patients with excellent recovery, and one with
scores of 2 to 42 (with deaths awarded 42), representing patients with
a worse outcome.
The third outcome in the hierarchy was BI (dichotomized into 0 to
90 versus 95 to 100) at 90 days.3 Because the planned analysis of
NIHSS was not significant, analysis of the BI was exploratory. CMH
and logistic regression testing were used and all probability values
are nominal.
Power Calculations Based on NIHSS
The NIHSS was included within the SAINT I trial protocol as an end
point without first examining statistical properties or undertaking
formal power calculations. The planned analysis of NIHSS was
nonsignificant and the approach clearly required review to inform
Figure 1. Distribution of change scores on the NIHSS, based on
the prespecified approach to analysis, final NIHSS score rec-
orded at 90 days, or last rating was subtracted from the base-
line score to generate a “change score.” For patients who had
died, a final score of 42 (worst category) was substituted. Thus,
for example, if a typical patient may have entered the trial with
an NIHSS score of 12, and improved by 90 days to a score of
5, then the “change score” would then be 7. However, if that
patient had died before 90 days, the assigned final score would
be 42, and the “change score” would be 30. Ninety-day mor-
tality in the trial was 17%.3 A basic assumption for the planned
analysis of covariance is that the change scores would be nor-
mally distributed; instead, the Figure reveals that these change
scores follow a bimodal and skewed distribution. Nonparametric
analysis is essential (see text).
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future trials, such as the sister trial, SAINT II. As part of our
exploratory analysis of the trial results, we have therefore considered
the power of various methods of analyzing NIHSS under various
sample sizes.
Because the NIHSS data fail to meet assumptions required for
parametric analysis, a power assessment based on ANCOVA would
be inappropriate and power calculations reported here are based on
a nonparametric approach using the CMH test. The model on which
the CMH test was calculated included the following variables for
analysis of NIHSS final and change scores: treatment (2 levels), side
of infarct (2 levels), stratified NIHSS baseline score (4 levels), and
intent-to-treat or treatment with alteplase (2 levels). Using our trial
data, a bootstrap method was used randomly to draw 5000 times with
replacement “n” patients from the NXY-059 and placebo groups.
The resulting CMH test for NIHSS final and change scores and for
the dichotomization approach were calculated for each random
sample. The power is defined as the percentage of CMH tests, which
resulted in P0.05, ie, as the sensitivity of the test to deliver a result
that reaches statistical significance at P0.05 when there exists a
genuine difference of a defined magnitude between treatments.
Results
We randomized 1722 patients, and mRS outcome data were
available for 1699 of the 1705 patients (99.6%) who received
any treatment: 850 were allocated to NXY-059 and 849 to
placebo. Mean age was 68.4 years and 947 (55.5%) were
male. Mean time from onset of stroke to treatment was 3
hours 46 minutes and 28.7% received alteplase. The treat-
ment groups were well balanced for baseline prognostic
variables.3
Outcome Measures
Outcomes according to mRS, NIHSS, and BI showed clear
benefit from NXY-059 treatment at 7 days with benefit still
present on BI and mRS at 30 days and on mRS by 90 days
(Figure 2). The benefits of treatment with NXY-059 demon-
strated on mRS at 90 days/last follow-up were consistently
noted across subgroups. Alternative methods of analysis
for mRS, dichotomized at the various possible thresholds
(0 versus 1 to 5; 0 to 1 versus 2 to 5, etc) or categorized into
3 groups (0 to 1 versus 2 to 3 versus 4 to 5) were internally
consistent, reaching significance for complete cure (mRS, 0;
P0.003), recovery of ambulation (mRS, 3; P0.02), and
for the trichotomy (P0.03). Neither the mortality nor the
proportion of patients who were severely disabled (mRS
5/death) was altered by treatment with NXY-059.3 There was
no significant effect on BI at last rating either on dichotomi-
zation (95 to 100 versus 0 to 90; 60 to 100 versus 0 to 55) or
by trichotomy (95 to 100 versus 60 to 90 versus 0 to 55).
Early outcomes were strongly positive, however. Point esti-
mates of odds ratios for efficacy according to all analyses of
functional measures showed similar trends toward benefit and
their CIs overlap widely: all domains of outcome improved to
a similar extent.
Stratification Variables
As expected, outcomes varied among strata (not shown), but
there was no interaction between the treatment effect of
NXY-059 and the stratification variables (Figure 3).
Baseline Characteristics
None of the baseline or medical history variables evaluated
showed apparent evidence of interaction with the treatment
effect of NXY-059 (Figures 4 and 5). Nominal probability
values were 0.05 for diastolic blood pressure and ischemic
heart disease; however, there was no adjustment for multi-
plicity, although at least 25 such tests were conducted, and no
biological rationale had been proposed for any interaction
between treatment and these effects.
Power Calculations Based on NIHSS
When the generalized CMH test with modified ridit scores
was applied we found that a trial of 1700 patients would have
power of only 16% to detect the difference between the
treatment groups using the change in NIHSS from baseline
score versus power of 35% to detect the observed differ-
ence in final NIHSS. Using dichotomization of final NIHSS
scores at 0 to 1 versus 2 to 42, power lies between these
values, at 24% (Table).
Discussion
SAINT I is the first trial of a putative neuroprotectant in acute
ischemic stroke to report a positive result on its primary end
point. Interpretation of these findings will be greatly assisted
when the twin trial, SAINT II, reports next year. Meantime,
we have closely examined our results seeking evidence of
confounding factors or subgroups that could be responsible
for a false-positive finding, and/or that may explain the
apparent discrepancy between the primary end point (mRS at
90 days) and the prespecified additional end points (NIHSS
and BI).
In essence, we have not identified any interaction between
treatment effect and either baseline variables or medical
history that could undermine our result. Not only was our trial
large enough for randomization to deliver reasonable balance
on prognostic factors, duly confirmed by our finding that the
variables that we measured were evenly distributed between
treatment groups,3 but also the formal tests for interaction
between treatment effect and these variables were uniformly
reassuring, ie, they have raised no evidence that any residual
imbalance in baseline variables influenced the study findings.
To assist with interpretation of interaction tests around an
overall odds ratio of 1.2 for treatment effect, it should be
noted that a study of this size will have 80% power to detect
an interaction when the odds ratio in one subgroup is at least
50% higher than the other.
Second, we found no subgroup interaction related to our
stratification variables that either would undermine our result
or suggest that we had included an unreasonably heteroge-
neous population. The treatment benefit is present regardless
of use of alteplase, side of stroke, or initial stroke severity. It
was also independent of time from stroke onset to treatment,
which we had rigorously controlled. The lack of interaction
with either rt-PA use or time to treatment deserves comment.
Certainly the experimental data support efficacy of NXY-059
across the 6-hour time window.6 Less time-dependency than
reported for alteplase1 may therefore be expected in the
SAINT trial. The limited power for the time-dependency
analysis and the preponderance of patients (two-thirds) being
treated within the narrow 3- to 5-hour delay also need to be
considered. It would be premature to conclude that the
benefits of treatment with NXY-059 are not time-dependent
2972 Stroke December 2006
 at GLASGOW UNIV LIB on January 23, 2012http://stroke.ahajournals.org/Downloaded from 
within the 6-hour window studied. Regarding use alongside
alteplase, the experimental data indicate that NXY-059 can
provide at least as good efficacy in the absence or presence of
reperfusion, ie, in a permanent focal ischemia model as in a
transient ischemia model.6 The subgroup analyses in SAINT
I are fully compatible with similar benefits being achieved
with NXY-059 treatment whether administered to patients
also treated with alteplase or given as monotherapy. Firmer
Figure 2. Efficacy outcomes for the SAINT I trial. The primary outcome measure was mRS at 90 days or last rating, as analyzed by the CMH
test with modified ridit score, adjusted for baseline stratification variables of stroke severity (NIHSS in 4 categories), side of infarct (right or left
hemisphere), and use or intended use of tissue plasminogen activator. The CMH test considers the full range of the mRS, with deaths
included at mRS 5. Odds ratios were estimated by logistic regression, adjusting in the same way as for the primary end point, and are shown
with their estimated 95% CIs, along with the probability value from the CMH test; however, because logistic regression uses a different algo-
rithm to the CMH test, it is possible for minor discrepancies to occur between the CMH probability value and the 95% CIs. The CMH proba-
bility value is the primary measure of significance. Only 4 of the analyses of mRS by dichotomization were prespecified as secondary mea-
sures (excluding 0 to 4 versus 5); trichotomization 0 to 1 versus 2 to 3 versus 4 to 5 was also prespecified. Analysis of mRS at 7 and 30 days
was prespecified. The analyses of final NIHSS shown in the Figure were conducted post hoc, after the planned approach to examine change
of NIHSS from baseline was considered inappropriate. NIHSS was not recorded at 30 days. The prespecified analysis of BI was to examine
the dichotomization at 95 to 100 versus 0 to 90 at 90 days or last rating; however, because the planned NIHSS analysis that lay higher in the
statistical hierarchy of end points was not significant, all analyses of BI are considered exploratory. For purposes of all analyses shown,
patients who died were awarded the worst score on the relevant scale. All analyses are based on the intent-to-treat principle.
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conclusions need to await the planned pooled analyses of the
SAINT trials after the completion of SAINT II, which will
have much greater power to detect differential response to
NXY-059 dependent on time to treatment or alteplase usage.
Third, we see consistency in effect sizes and directions
among 3 measures of stroke outcome: disability, neurological
status, and activities of daily living. We also see consistency
across the follow-up period, with greater effects at 7 and 30
days than at 90 days. The more profound time-related effect
on NIHSS than mRS is consistent both with an effect on
neurological status that later translates into a benefit on
disability, and with the expected dilution of treatment effects
by unrelated conditions that occur after stroke. Taken to an
extreme, if outcome were tested 10 years after acute ischemic
stroke, the incidence of unrelated ischemic heart disease,
cancer, and death would be so high in both groups that any
beneficial effect of NXY-059 on stroke disability would
likely be diluted to undetectable levels. As expected, the mRS
was consistently the most sensitive efficacy variable.15 The
lesser sensitivity of NIHSS and BI may contribute to their
lack of statistical significance at some of the later assess-
ments. The BI considers only the need for help with activities
of daily living and not the presence of symptoms or loss of
social activities. It is known to suffer ceiling effects, ie, it fails
to detect milder forms of disability, and will therefore lose
sensitivity as recovery progresses across time from stroke.16
A 90-day follow-up period has long been a standard within
the field to account appropriately for the time course of
functional recovery.16,17 Assessment at earlier time points
may, however, as evidenced by the present trial, be more
sensitive in determining the existence of a treatment response.16
The main potential concern raised by the SAINT I trial
results was the apparent lack of correspondence between the
mRS and NIHSS. Here, we see that our failure to affect
NIHSS is primarily a statistical fallacy, because the odds
ratios, CIs, and probability values of the exploratory NIHSS
tests correspond well with those for mRS and BI: the
prespecified test was inappropriate and in retrospect was
chosen in error. There is accumulating evidence to suggest
that mRS may be the optimal end point for phase III stroke
trials based on statistical, clinical, and regulatory grounds, in
preference to grading a neurological examination or to ana-
lyses of the BI.15–19 The SAINT I trial was designed to deliver
90% power to detect an effect on mRS equivalent to a
common odds ratio of 1.3; we actually observed a common
odds ratio of 1.2. We have also examined the power of a trial
of 1700 patients to detect a benefit on NIHSS under these
circumstances and found that a trial of that size will have
20% power to declare significance with the observed effect
on change in baseline in NIHSS but 35% for detecting the
Figure 3. Efficacy outcomes of the SAINT I trial according to stratification variables. The primary outcome measure was mRS at 90
days or last rating, as analyzed by the CMH test with modified ridit score, adjusted for baseline stratification variables of stroke severity
(NIHSS in 4 categories), side of infarct (right or left hemisphere), and use or intended use of tissue plasminogen activator. The CMH
test considers the full range of the mRS, with deaths included at mRS 5. Odds ratios were estimated by logistic regression, adjusting in
the same way as for the primary end point, and are shown with their estimated 95% CIs, along with the probability value from the
CMH test; however, because logistic regression uses a different algorithm to the CMH test, it is possible for minor discrepancies to
occur between the CMH probability value and the 95% CIs. The CMH probability value is the primary measure of significance. Interac-
tions between the prognostic variables used in the stratification algorithm and the treatment effect were tested using the CMH test, and
the probability value for each of these is shown in the Figure. Because none of these was significant, the individual odds ratios and
their 95% confidence limits are provided only for illustration. A more reliable estimate of treatment effect is obtained from the primary
outcome in Figure 2. For purposes of all analyses shown, patients who died were awarded the worst score on the relevant scale. All
analyses are based on the intent-to-treat principle.
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Figure 4. Efficacy in SAINT I trial according to baseline variables. The primary outcome measure was mRS at 90 days or last rating, as
analyzed by the CMH test with modified ridit score, adjusted for baseline stratification variables of stroke severity (NIHSS in 4 catego-
ries), side of infarct (right or left hemisphere), and use or intended use of tissue plasminogen activator. The CMH test considers the full
range of the mRS, with deaths included at mRS 5. Odds ratios were estimated by logistic regression, adjusting in the same way as for
the primary end point, and are shown with their estimated 95% CIs, along with the probability value from the CMH test; however,
because logistic regression uses a different algorithm to the CMH test, it is possible for minor discrepancies to occur between the CMH
probability value and the 95% CIs. The CMH probability value is the primary measure of significance. Interactions between the baseline
variables recorded and the treatment effect were tested using the CMH test, and the probability value for each of these is shown in the
Figure. No adjustment has been made for multiplicity. Interpretation should be cautious in light of the large number of such exploratory
tests: as an approximate guide, Bonferroni correction would suggest that a probability value of 0.002 would indicate a “significant”
interaction. Because none of these was significant, the individual odds ratios and their 95% confidence limits are provided only for
illustration: a more reliable estimate of treatment effect is obtained from the primary outcome in Figure 2. For purposes of all analyses
shown, patients who died were awarded the worst score on the relevant scale. All analyses are based on the intent-to-treat principle.
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Figure 5. Efficacy in SAINT I trial according to medical history. The primary outcome measure was mRS at 90 days or last rating, as
analyzed by the CMH test with modified ridit score, adjusted for baseline stratification variables of stroke severity (NIHSS in 4 catego-
ries), side of infarct (right or left hemisphere), and use or intended use of tissue plasminogen activator. The CMH test considers the full
range of the mRS, with deaths included at mRS 5. Odds ratios were estimated by logistic regression, adjusting in the same way as for
the primary end point, and are shown with their estimated 95% CIs, along with the probability value from the CMH test; however,
because logistic regression uses a different algorithm to the CMH test, it is possible for minor discrepancies to occur between the CMH
probability value and the 95% CIs. The CMH probability value is the primary measure of significance. Interactions between the medical
history variables recorded and the treatment effect were tested using the CMH test, and the probability value for each of these is
shown in the Figure. No adjustment has been made for multiplicity. Interpretation should be cautious in light of the large number of
such exploratory tests: as a rough guide, Bonferroni correction would suggest that a probability value of 0.002 would indicate a “signifi-
cant” interaction. As none of these was significant, the individual odds ratios and their 95% confidence limits are provided only for
illustration: a more reliable estimate of treatment effect is obtained from the primary outcome in Figure 2. For purposes of all analyses
shown, patients who died were awarded the worst score on the relevant scale. All analyses are based on the intent to treat principle.
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observed difference in final NIHSS score. The CMH test is a
nonparametric rank-based test across categorized data. The
ranks across values of total NIHSS are different and less
variable than the ranks across the change from baseline, both
being adjusted for the stratification variables. In our trial, we
observed values for individual patients’ final score that
ranged from 0 to 42 (43 categories), and for their change
score that ranged from 23 to 36 (50 categories) (Figure 1).
This increase in number of categories weakens the test. The
SAINT II trial (NCT 0006101022) has now been expanded
from 1700 patients to 3200 to enhance its power (to 80%) to
confirm our result on mRS. The sample size change was
based entirely on mRS considerations. This revision has been
reviewed and approved by the relevant ethics committees and
regulatory authorities. The secondary analysis has been
changed to examine total NIHSS at last rating using the CMH
test across all categories; however, even these combined
changes will deliver under 60% power to confirm a similar
benefit as in SAINT I on NIHSS (Table). NIHSS therefore
remains a secondary end point of SAINT II, after analysis of
the mRS as primary end point.
Discussion of statistical power should not detract from the
important question of clinical utility. The greatest advances in
health derive from modest benefits that can be applied to
populations rather than life-saving surgery for a few. On
present estimates, a one-grade improvement in mRS appears
likely to occur once among every 7 or 8 patients treated, and
the need for a wheelchair avoided once for every 27 patients
treated.3 Six million new strokes occur per annum worldwide.
To individual patients, clinicians could explain that NXY-059
may improve their odds of avoiding more severe forms of
disability by 20% and, that left untreated, most patients will
have some degree of long-term symptoms or disability, but
that NXY-059 treatment could bring an extra 1 in 8 patients
out of long-term symptoms or confinement to a wheelchair.
The “cure rate” will increase from 1 in 9 to 1 in 6 or 7.
There are risks associated with exploratory analyses of
trials, especially when the main treatment effect has been
only modestly positive. Our analyses presented here make it
neither more nor less likely that the initial finding was caused
entirely by chance; the probability of a false-positive result
remains 0.038. We remain cautious in our use and interpre-
tation of these exploratory analyses. However, they are based
on the intention-to-treat principle; where exploratory analyses
have been undertaken we have reported all rather than a
subset and have done so without adjustment for multiplicity;
our exploratory analyses are based only on predefined vari-
ables, ie, those that were prospectively collected at study
entry; and in instances in which statistical methodology
diverges from the protocol-defined approach, we have used
the method from our protocol or from the literature that most
closely matches the original intention. For example, the
analysis of NIHSS outcomes using dichotomization between
0 and 1 and 2 and 42 is not the most sensitive to reveal a
treatment effect in our dataset but as the method most widely
reported elsewhere has been reported here.13,14 We have
simultaneously reported the results using the CMH test,
which matches our primary analysis.
In summary, we report reassuring findings from explor-
atory analyses of interactions with baseline variables and of
subgroups in the SAINT I trial. Although only our primary
end point was positive on prespecified analysis, examination
of additional analyses of each of the main outcome measures
at various intervals after trial entry reveals supportive trends
toward benefit. The power of a study of the size of SAINT
I to detect useful clinical benefit on additional outcomes
measured by NIHSS or BI is low, and only a larger confir-
matory trial such as SAINT II will provide conclusive
evidence of whether NXY-059 is effective in limiting dis-
ability after acute ischemic stroke.
Appendix
The following participated in the SAINT I study: Steering Com-
mittee, K. R. Lees, Glasgow, United Kingdom (chair); J. A. Zivin,
San Diego, Calif (joint chair, planning and conduct stage), T.
Ashwood, So¨derta¨lje, Sweden (sponsor representative); A. Davalos.
Barcelona, Spain; S. Davis, Melbourne, Australia; H. C. Diener,
Essen, Germany; J. Grotta, Houston, Tex; P. Lyden, San Diego,
Calif; A. Kakarieka (sponsor representative: planning and conduct
stage); S. Sheth, Wilmington, De (sponsor representative: analysis
and reporting stage); A. Shuaib, Edmonton, Canada; W. Wasiewski,
Wilmington, De (sponsor representative); Data and Safety moni-
toring board, S. Pocock, London, United Kingdom (chair); H.
Adams, Iowa City, Iowa; P. Bath, Nottingham, United Kingdom; D.
Oakes, Rochester, NY; N. G. Wahlgren Stockholm, Sweden. Study
team leader, Karin So¨derberg, So¨derta¨lje, Sweden; Study Team
Physician, H. G. Hårdemark; Study team statisticians, V. Alderfer,
Wilmington, De; A. Gro¨nblad, So¨dertalje, Sweden; U. Emeribe,
Wilmington, De. Contract Research Organizations, Covance Cen-
tral laboratory Services, Perceptive Informatics, eResearch technol-
ogy Ltd, Fisher Clinical Services. Investigators, refer to N Engl
J Med article.3
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